- The social value of clinical research.Michelle Gjl Habets, Johannes Jm van Delden & AnneLien L. Bredenoord - 2014 - BMC Medical Ethics 15 (1):66.details
|
|
(1 other version)Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene.Trudo Lemmens - 2004 - Journal of Law, Medicine and Ethics 32 (4):641-657.details
|
|
Corporate Disguises in Medical Science: Dodging the Interest Repertoire.Sergio Sismondo - 2011 - Bulletin of Science, Technology and Society 31 (6):482-492.details
|
|
Assessing risk/benefit for trials using preclinical evidence: a proposal.Jonathan Kimmelman & Valerie Henderson - 2016 - Journal of Medical Ethics 42 (1):50-53.details
|
|
Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation.Jodi Halpern, David Paolo & Andrew Huang - 2019 - Journal of Medical Ethics 45 (6):384-387.details
|
|
Why Most Published Research Findings Are False.John P. A. Ioannidis - 2005 - PLoS Med 2 (8):e124.details
|
|
Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. [REVIEW]Joel Lexchin - 2012 - Science and Engineering Ethics 18 (2):247-261.details
|
|
(1 other version)The ICMJE Recommendations.Alastair Matheson - 2016 - BMC Medical Ethics 17 (1):1-10.details
|
|
(1 other version)Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.details
|
|
Redundant, Secretive, and Isolated: When Are Clinical Trials Scientifically Valid?Kirstin Borgerson - 2014 - Kennedy Institute of Ethics Journal 24 (4):385-411.details
|
|
(1 other version)Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene.Trudo Lemmens - 2004 - Journal of Law, Medicine and Ethics 32 (4):641-657.details
|
|
(1 other version)Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.details
|
|
(1 other version)The ICMJE Recommendations and pharmaceutical marketing – strengths, weaknesses and the unsolved problem of attribution in publication ethics.Alastair Matheson - 2016 - BMC Medical Ethics 17 (1):1-10.details
|
|